Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer.

about

Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer.

Item

http://www.wikidata.org/entity/Q51746738

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@en

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@nl

type

Item

label

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@en

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@nl

prefLabel

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@en

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@nl

P1476

Antitumor activity of HPA3P th ...... ic cell death in colon cancer.

@en

P2093

Chang Ho Seo

http://www.w3.org/2001/XMLSchema#string

Eugene Cho

http://www.w3.org/2001/XMLSchema#string

Eunji Park

http://www.w3.org/2001/XMLSchema#string

Jong-Kook Lee

http://www.w3.org/2001/XMLSchema#string

Tudor Luchian

http://www.w3.org/2001/XMLSchema#string

Yoonkyung Park

http://www.w3.org/2001/XMLSchema#string

P2860

Studies on anticancer activities of antimicrobial peptides

Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

Cancer drug resistance: an evolving paradigm

High-mobility group box 1 and cancer.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Safety of oxaliplatin in the treatment of colorectal cancer.

Describing the mechanism of antimicrobial peptide action with the interfacial activity model

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Molecular mechanisms of drug resistance.

P304

7902-7917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24083

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29487701

http://www.w3.org/2001/XMLSchema#string

P932

5814268

http://www.w3.org/2001/XMLSchema#string